Business Parks & Science Centres



Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 600x94px
Document › Details

BRAIN AG. (12/6/11). "Press Release: Brain and Autodisplay Biotech Cooperate. Joint Development of Innovative Screening Systems on the Basis of Cellularly Exposed Human Protein Systems". Zwingenberg & Düsseldorf.

Organisations Organisation BRAIN Biotechnology Reserarch and Information Network AG (FSE: BNN)
  Group BRAIN (Group)
  Organisation 2 Autodisplay Biotech GmbH
Products Product gene expression technology
  Product 2 cosmetics
Persons Person Maas, Ruth (Autodisplay Biotech GmbH 201112 Managing Director)
  Person 2 Eck, Jürgen (BRAIN 201507– CEO before CTO + Co-founder)

The white biotechnology company BRAIN AG and Autodisplay Biotech GmbH have announced a co-operation to develop innovative cellular screening systems today. The strategic collaboration aims at using the benefits of the exposition of cosmetically relevant human target molecules on the surface of screening cells in the search for new cosmetic actives. BRAIN cooperates with Autodisplay Biotech, a technological leader in bacterial surface expression of proteins, a move which perfectly complements BRAIN's own screening systems and thus strategically expands the company's technology platform.

For BRAIN the collaboration announced today represents another important milestone in its corporate strategy to intensify co-operation with technology companies in order to drive forward the research and development of novel cosmetic actives.

For Autodisplay Biotech co-operating with BRAIN paves the way for a consistent further development of its own technology. The use of the surface expression technology and its direct application constitutes a tailor-made solution for the identification of bioactives within the project.

"The co-operation with BRAIN once more proves that Autodisplay Biotech has successfully employed its technology in the past to build up a valid, industrially relevant screening system, opening up new opportunities for difficult-to-access targets in particular. Thanks to BRAIN's internal resources - bioactives and natural substances - we can now quickly find and find new active ingredients and explaind the methods of action," says Dr. Ruth Maas, CEO of Autodisplay Biotech.

"This strategic co-operation helps us tap into an immense potential for synergy, which will make those human target molecules in particular accessible to an intensive BioActives screening which would not be accessible using traditional technologies," explains Dr Jürgen Eck, Chief Scientific Officer of BRAIN AG. "Screenings for new modes of action, a core competency of white biotechnology, have been at the top of BRAIN's agenda for many years as they offer an immense potential for growth. This is why we are looking very much forward to intensively using and jointly advancing the synergies resulting from the co-operation between the two companies."


BRAIN AG is an industrial "white" biotech company which discovers and develops novel bioactive natural compounds and proprietary enzymes for its partners and customers in the chemical and pharmaceutical industries, as well as the food and cosmetics industries. With its unique approach to the discovery and production of new biological compounds and biocatalysts, the company achieves creative solutions by harnessing nature's untapped biodiversity. Its success is built on its proprietary BioArchive comprising millions of genes, proteins and metabolic pathways from microbial isolates and metagenome libraries. Since its foundation in 1993, BRAIN has entered into over 70 strategic collaborations with nearly all the relevant companies within the chemical industry as e.g. BASF, Ciba, Clariant, Evonik Degussa, DSM, Genencor, Henkel, Nutrinova, RWE, Sandoz, Schering, Südzucker and Symrise, to name but a few. Currently, BRAIN employs 99 highly skilled people.

For their groundbreaking industrial biotechnology activities for a sustainable "biologisation of the chemical industry" using nature`s toolbox for industrial processes, BRAIN with its CEO Dr. Holger Zinke received the "Deutschen Umweltpreis 2008" of the "Deutsche Bundesstiftung Umwelt", DBU.

About Autodisplay Biotech

Autodisplay Biotech GmbH are technology leaders in bacterial surface expression. Using this technology, anything from simple peptides to complex proteins can be presented on the surfaces of bacteria and thus may be used to identify innovative products in the biocatalysis and bioanalytics fields of the chemicals and pharmaceuticals industry. Ever since its foundation as a spin-off from Düsseldorf's Heinrich Heine University in 2008, Autodisplay Biotech's founders Prof. Dr. Jose, Dr. Ruth Maas and Dr. Gunter Festel and their six employees have focussed on the consistent further development of their proprietary technology. This will permit the company to offer intelligent solution-oriented screening and production systems for the bio-based industry of tomorrow.

Record changed: 2017-04-02


Picture [LSUS] – The Business Web Portal 600x60px

More documents for BRAIN (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 600x94px

» top